Predictive factors for postoperative medication therapy for overactive bladder symptoms after holmium laser enucleation of prostate

Abstract

ObjectiveTo preoperative factors that could predict the persisting storage symptoms after Holmium laser enucleation of the prostate (HoLEP).MethodsMedical records of 257 patients who underwent HoLEP between December 2014 and January 2021 were reviewed. Participants with a follow‐up period exceeding 6 months were included. Preoperative data, including International Prostate Symptom Score (IPSS), uroflowmetry, prostate size, and prostate‐specific antigen, were collected. All participants underwent a preoperative urodynamic study. The correlation between perioperative variables and postoperative medication therapy (antimuscarinics or beta‐3 agonists) was assessed.ResultsOut of 257 participants in the study, 46 (18.6%) were allocated to the medication group, of which 25 (54.3%) initiated medication therapy postoperatively. The medication group showed worse postoperative IPSS storage symptom score and quality of life score compared to the medication‐free group (p = 0.048 and p = 0.002, respectively), but no significant differences were observed in complications or operative variables. In the de‐novo medication group, patients had lower preoperative Qmax, larger prostate volume, and smaller maximum cystometric capacity (MCC) compared to the persisting medication group (p = 0.020, p = 0.009, and p = 0.008, respectively). Overactive bladder (OAB) history, terminal detrusor overactivity (DO), and IPSS urgency item were identified as possible predictive factors for post‐HoLEP medication use.ConclusionsPreoperative factors such as OAB history, terminal DO, and IPSS urgency item may predict the need for post‐HoLEP medication therapy. Further follow‐up studies are warranted to understand the characteristics of the de‐novo medication group due to the significant discomfort it can cause to patients.